BAXTER ISSUES VOLUNTARY NATIONWIDE RECALL OF CEFAZOLIN IN DEXTROSE INJECTION, USP, 2G / 100ML (20MG / ML) SINGLE-DOSE INFUSION BAG IN 100ML DUE TO PARTICULATE MATTER FOUND IN SOLUTION

Media Contact:
Brenna Byrne (224) 948-5353
media@baxter.com

FOR IMMEDIATE RELEASE - July 24, 2026 – DEERFIELD, Ill., Baxter International Inc. (NYSE:BAX) is voluntarily recalling Lot LD175708, Exp 14-Feb 2027 of **Cefazolin in Dextrose Injection** due to a report of particulate matter found in the solution identified as cardboard.

Risk Statement: The use of the defective product has a reasonable probability of causing pulmonary emboli (blockage in pulmonary blood vessels), occlusions of other blood vessels (which can lead to tissue death and possible organ damage), and/or phlebitis (inflammation of the walls of veins, which may lead to clotting). Systemically, foreign particles infused intravenously can cause systemic activation of the immune system, organ dysfunction, and hemolysis (breakdown of blood cells). To date, Baxter has not received any reports of adverse events related to this issue.

Affected Product:
This product is used intravenously to treat bacterial infections or prevent them during surgery

Product Code	Product Description	Lot Number	Expiration Date	NDC Number
2G3508	Cefazolin in Dextrose Injection, USP, 2g / 100mL (20mg / mL) Single-Dose Infusion Bag in 100mL GALAXY Plastic Container, Frozen Premix	LD175708	14-Feb-2027	0338-3508-41

The affected lots can be identified by locating the lot number and expiration date on the front of the product package and the label attached to the carton, as shown in the images below.



The impacted product was distributed from 3/25/2025 to 6/30/2025 in the United States.

Customers should immediately discontinue use of and return all affected units in accordance with their facility's process. Baxter is contacting customers with instructions on how to identify and return the impacted product.

For general questions regarding this communication, please contact Baxter Healthcare Center for Service at 888-229-0001 between the hours of 7:00 am and 6:00 pm Central Time, Monday through Friday.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

- Complete and submit the report **Online**: www.fda.gov/medwatch/report.htm

- **Regular Mail or Fax**: Download form www.fda.gov/MedWatch/getforms.htm2 or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

The United States Food and Drug Administration (FDA) has been notified of this action.

###